close
Add to watchlist
Sunesis Pharmaceuticals Inc (SNSS) Healthcare, Major Drugs
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin. It was formerly known as Mosaic Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in South San Francisco, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.46 |
| Volume | 840293 |
| Volume Avg | 253033 |
| 52 Week High | 3.16 |
| 52 Week Low | 1.01 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.47 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | -1000% |
| EPS change Q/Q next Q est | -1000% |
| EPS change Y/Y | -1328.57% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.18 |
| EPS next Y est | -0.70 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |